The Latest TOP10 Ranking of Global CRO Companies

Former Fierce Markets writer and current independent writer Arsalan Arif recently published the latest ranking of global CRO companies. Let me share with you here that the ranking is based on market value. The data source is mainly based on the financial reports of listed companies, while the unlisted companies are estimated by reliable information sources (unit: billion US dollars). Since the founding of our company in 2004, Medicilon has grown into one of the professional drug discovery contract research organizations (CRO) in China.

Quintiles has undoubtedly continued to rank No. 1 in the market value ranking of CRO companies. Dennis Gillings co-founded Quintiles with several other partners in 1982. Quintiles has since been involved in clinical trials of pharmaceutical companies. With expertise and expertise in clinical trials, business capabilities surpassed employers, and soon became one of the few CRO companies in the world, until now Quintiles is still the world’s largest CRO company.

After the CRO industry has undergone a series of integrations, many small companies have merged into large companies. The gap between companies has gradually narrowed and industry competition has become increasingly fierce. The areas covered by the entire CRO industry service are also expanding. From candidate compounds, to early clinical trials, to the final market promotion, CRO companies participate in the entire process. As the entire industry continues to evolve, many outstanding companies have come to the fore, including PPD, Parexel, Icon, PRA Health Sciences, Covance, INC Research / inVentiv Health, and local company Wuxi AppTec (Wuxi).

In order to keep itself in an invincible position in the fierce competition, strengthen the integration with cross-fields, especially highlight the strategic position of data resources, last year, Quintiles and IMS Health completed the merger, IMS Health is the world’s largest provider of doctor prescription data , Also provides drug pricing and market services for pharmaceutical companies.

Another way to strengthen itself is through synergies between peers, including LabCorp’s acquisition of Covance, and the merger of INC and inVentiv Health.

This time, the CRO companies are ranked from the perspective of market capitalization. Both the market capitalization data and the number of employees are derived from corporate documents/financial reports, and the deadline is set on August 30. The two companies ranked 10th, which is for reference by the original author. The conclusion reached after the opinions of industry professionals.

QuintilesIMS

Market value: $20.7 billion

2016 revenue: $5.4 billion

Number of employees: 50,000

CEO: Ari Bousbib

LabCorp/Covance

Market value: $15.66 billion

2016 LabCorp revenue: $6.6 billion

Covance in 2016: $2.8 billion

Number of LabCorp employees: 36,000

Number of Covance employees: 16,000

LabCorp CEO: David King

Covance CEO: John Ratliff

PPD

Estimated value: 9.05 billion US dollars

Number of employees: 19,000

CEO: David Simmons

Icon

Market value: $6.08 billion

2016 revenue: $1.7 billion

Number of employees: 12,500

CEO: Steve Cutler

INC Research/inVentiv Health

Market value: $6.04 billion

2016 revenue: $2.1 billion

Number of employees: 22,000

CEO: Alistair Macdonald

PRA Health Sciences

Market value: $4.8 billion

2016 revenue: $1.8 billion

Number of employees: 13,000

CEO: Colin Shannon

PAREXEL

Market value: $4.5 billion

2016 revenue: $2.1 billion

Number of employees: 18,900

CEO: Josef von Rickenbach

BioClinica

Estimated value: 1.4 billion US dollars

CEO: John Hubbard

Medpace

Market value: $1.2 billion

2016 revenue: $371 million

Number of employees: 2,500

CEO: August Troendle

Premier Research

CEO: Ludo Reynders

Worldwide Clinical Trials

CEO: Neal Cutler

Reference source: The top10 biopharma CROs in the world—mid-2017 edition

Original Title: Global TOP10 CRO Companies (2017 Mid Edition)

TOP 10 New CRO Companies in China

R&D CRO List- 2020 China’s Top 20 CRO Companies

Top Ten Global CRO Companies

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客